Fluorescein angiography

Wet Age-Related Macular Degeneration - Pipeline Insight, 2023: Comprehensive Analysis on 80+ Upcoming Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023

This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-related Macular Degeneration pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-related Macular Degeneration pipeline landscape.
  • A detailed picture of the Wet Age-related Macular Degeneration pipeline landscape is provided which includes the disease overview and Wet Age-related Macular Degeneration treatment guidelines.
  • The companies which have their Wet Age-related Macular Degeneration drug candidates in the most advanced stage, i.e.
  • Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD

Retrieved on: 
Monday, March 6, 2023

CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics announced today that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program, demonstrated favorable efficacy in an animal model of neovascular age-related macular degeneration (AMD) in rhesus monkeys. This animal model is characterized not only by the abnormal growth of new blood vessels behind the retina, as shown in Figure 1, but also by retinal fibrosis and vascular hemorrhage, which are the critical characteristics of Wet-AMD, Dry-AMD, and GA. While it is difficult to extrapolate the visual acuity score in animals, the damage prevented by NM3086 in this model suggests the drug's efficacy in treating the disease.

Key Points: 
  • The lead drug candidate NM3086 prevented hemorrhage, fibrosis, and neovascularization in a 28-day disease model in rhesus monkeys.
  • While it is difficult to extrapolate the visual acuity score in animals, the damage prevented by NM3086 in this model suggests the drug's efficacy in treating the disease.
  • Figure 1: Fluoresceine angiogram data from three animals treated with NM3086 (bottom) and three that received placebo control.
  • Scientists of Charles River Laboratories established a preclinical Choroidal Neovascularization (CNV) efficacy model in rhesus monkeys.

Worldwide Angiography Equipment Industry to 2028 - by Device, Procedure, End-users and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022

The global angiography equipment market is segmented based on the device, procedure, and end-users.

Key Points: 
  • The global angiography equipment market is segmented based on the device, procedure, and end-users.
  • Based on the device, the market is segmented into angiography systems, computed tomography angiography, digital subtraction angiography, magnetic resonance angiography, catheters tube, guide wires, balloons, and others including vascular closure devices and other accessories.
  • Based on the procedure, the market is sub-segmented into coronary angiography, fluorescein angiography, microangiography, neuro-vascular angiography, and peripheral angiography.
  • Geographically the global angiography equipment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

Nonmydriatic Handheld Fundus Cameras Global Market Report 2022: Steady Pace of Technological Advancements Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022

The "Nonmydriatic Handheld Fundus Cameras - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nonmydriatic Handheld Fundus Cameras - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Fundus cameras are typically used in applications such as fundus imaging, fluorescein angiography, paired optic disk images and external photograph.
  • The market is being driven by steady pace of technological advancements, growing awareness about eye care, increasing geriatric population and favorable government initiatives.
  • The incorporation of digital technology and artificial intelligence are also some of the factors propelling growth of nonmydriatic handheld fundus cameras.

Global Retinal Imaging Devices Market Report 2022: Integrating Artificial Intelligence in Retinal Imaging Devices Key for Future Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022

The "Retinal Imaging Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device Type, and End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Imaging Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device Type, and End-User" report has been added to ResearchAndMarkets.com's offering.
  • Penetration of low-cost retina imaging devices will spur the retinal imaging devices market during the forecast period.
  • Based on device type, the global retinal imaging devices market has been segmented into fluorescein angiography, fundus camera and optical coherence tomography (OCT).
  • Based on end-user, the global retinal imaging devices market is segmented into hospitals and clinics, specialty clinics, ambulatory care centers, and others.

Global Retinal Imaging Devices Market Research Report to 2027 - Featuring Argus Science, Basler and Olympus Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022

What are the inhibiting factors and impact of COVID-19 shaping the Global Retinal Imaging Devices Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Retinal Imaging Devices Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Retinal Imaging Devices Market?
  • What is the market share of the leading vendors in the Global Retinal Imaging Devices Market?
  • What modes and strategic moves are considered suitable for entering the Global Retinal Imaging Devices Market?

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

Retrieved on: 
Thursday, May 5, 2022

The presentation, titled Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy, was held on Sunday, May 1, 2022, and appeared in a session on clinical and translational research and AMD therapies excluding anti-VEGF.

Key Points: 
  • The presentation, titled Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy, was held on Sunday, May 1, 2022, and appeared in a session on clinical and translational research and AMD therapies excluding anti-VEGF.
  • Dr. Jason Slakter, MD, Clinical Professor, Department of Ophthalmology at NYU Grossman School of Medicine, presented.
  • The ARVO poster presented results of a pre-specified subgroup analysis of subjects with Polypoidal Choroidal Vasculopathy (PCV type CNV) enrolled in the Phase 2b randomized, sham-controlled study of patients with treatment naive exudative AMD.
  • In this study, subjects received either monotherapy with ranibizumab (Lucentis) or combination therapy with ranibizumab and one of two doses of OPT-302.

$2.06 Billion Opportunities in the Retinal Imaging Devices Global Market up to 2028 - By Device Type and End-User - ResearchAndMarkets.com

Retrieved on: 
Monday, March 14, 2022

The "Retinal Imaging Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device Type, and End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Imaging Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device Type, and End-User" report has been added to ResearchAndMarkets.com's offering.
  • The retinal imaging devices market is projected to reach US$ 3.00 billion by 2028 from US$ 2.06 billion in 2021; it is estimated to grow at a CAGR of 5.6% during 2021-2028.
  • Penetration of low-cost retina imaging devices will spur the retinal imaging devices market during the forecast period.
  • Based on device type, the global retinal imaging devices market has been segmented into fluorescein angiography, fundus camera and optical coherence tomography (OCT).

Outlook on the Choroidal Neovascularization Global Market to 2026 - by Product Type, Type of Diagnosis, Treatment Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 30, 2021

Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.

Key Points: 
  • Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.
  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What is the structure of the global choroidal neovascularization market and who are the key players?

Insights on the Diabetic Retinopathy Global Market to 2026 - Featuring Alimera Sciences, Allergan and Bayer Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, August 16, 2021

The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020.
  • Looking forward, the publisher expects the market to grow at a CAGR of 5.6% during 2021-2026.
  • Diabetic retinopathy (DR) refers to the damage caused to the blood vessels in the retina by diabetes mellitus.